GENE ONLINE|News &
Opinion
Blog

2023-06-19| R&D

Novel Pathway for Metastatic Cancer Therapy: Targeting Mitochondrial Plasticity

by GeneOnline
Share To

A study by researchers at UT Southwestern Medical Center shows that manipulation of mitochondrial shape could mitigate metastatic cancer. Their findings, published in Nature Cancer, indicate that cancer cells that have migrated are able to survive by undergoing a metabolic switch that reprograms their dependency from carbohydrates to fatty acids.  

Related Article: The Emergence of Metabolic Therapy, Unlocking a Next-Generation Cancer Treatment Strategy

Preventing Brain Metastases 

Metastatic cancer occurs when cancer cells fragment from the original tumor and migrate to other parts of the body. The team led by Srinivas Malladi, Ph.D., Assistant Professor of Pathology at UT Southwestern, focused on studying how escaped cancer cells are able to live in different parts of the body before emerging as metastatic cancer. Malladi commented, “Through mitochondrial plasticity, these cancer cells undergo metabolic reprogramming that aids their survival in the brain niche that otherwise would not be available to them. Exploiting this vulnerability could offer a way to prevent brain metastases,”. 

They used a mouse model to isolate late metastatic cells (Lat) from their brains. These cells have distinctly shaped, dot-like, mitochondria when compared to primary tumor cells, which have an elongated tubular shape. Additionally, the cells used fatty acid oxidation (FAO), suggesting that the change in shape is needed for the metabolism of fatty acids. They went on to examine whether metabolic reprogramming and FAO were possible as a result of altered mitochondrial dynamics by studying dynamin-related protein 1 (DRP1). The researchers observed a loss in cells ability to metabolize fatty acids and a return to their tubular shape after a decrease in the amount of DPR1. As well as a lower  probability of survival after the inhibition of DPR1. 

Potential for Development of New Therapies 

Understanding the traits and vulnerabilities of these cells is critical for developing strategies to prevent metastasis. The study revealed the importance of mitochondrial plasticity and its role in the survival of late metastatic cells. The researchers intend to evaluate DRP1 inhibitors to examine whether their effects could slow, prevent, or reverse metastatic cancer. The results are promising and open new avenues for the development of new therapies.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
GSK Successfully Acquires Clinical-Stage Company IDRx, Inc. to Enhance Cancer Treatment Options
2025-03-03
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
R&D
UT Southwestern Study Unveils Acidic Defense Mechanism of Cancer Cells
2024-04-09
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top